Cytochroma hopes to advance its three lead products for kidney disease patients, with an infusion of cash from the closing of a C$45 million (US$44 million) Series C financing and C$105 million licensing deal with Japanese drugmaker Mitsubishi Tanabe Pharma Corp. (BioWorld Today) Read More